Pfizer vs. Healthpeak: Which 6% Dividend Has Better Support?

Pfizer and Healthpeak Properties both offer income investors yields above 6%, but their dividends rest on very different engines. Pfizer must replace declining COVID revenue and convert its drug pipeline into cash. Healthpeak must keep healthcare properties occupied and fund acquisitions without stretching its balance sheet.

The original comparison showed Healthpeak with the wider payout cushion. Pfizer offers more potential upside from new products, but also more uncertainty around cash conversion.

Pfizer's products are growing, but cash coverage is tight

Pfizer raised the midpoint of its 2026 revenue guidance by $500 million in August, setting a range of $60.5 billion to $62.5 billion. Revenue from launched and acquired products, including Padcev, Nurtec and the Vyndaqel family, grew 18% operationally in the second quarter.

That growth is important because Pfizer expects about $4 billion of 2026 COVID-product revenue, below its earlier expectation of roughly $5 billion. The company needs newer medicines to offset that decline and the eventual loss of exclusivity for older products.

The original analysis estimated that Pfizer's dividend consumed 89% of free cash flow for the 12 months through June 28, 2026. Free cash flow is volatile and differs from earnings, but a payout near that level leaves less room for debt reduction, acquisitions or setbacks in the pipeline. Pfizer declared a fourth-quarter dividend of $0.43 a share, continuing its regular cash distribution.

Healthpeak's payout has more room

Healthpeak pays $0.10167 monthly, equal to $1.22 annually. Its updated 2026 adjusted FFO guidance was $1.73 to $1.77 a share. At the midpoint, the payout equals about 70% of adjusted FFO guidance.

That cushion is meaningful, but it is not risk-free. Healthpeak has cut its dividend in the past, and healthcare real estate faces tenant, reimbursement, staffing and interest-rate risks. The company also continues to allocate capital into senior housing, making operating execution important.

Pfizer and Healthpeak use different cash-flow measures, so their payout ratios should not be treated as perfectly comparable. Pfizer's free cash flow reflects companywide cash generation after capital spending. A REIT's AFFO adjusts property earnings and other items to approximate recurring distributable cash.

The better fit depends on the objective

Healthpeak currently offers the clearer dividend cushion and monthly payments. Pfizer offers a large pharmaceutical pipeline and could improve coverage if acquired and launched products continue to grow.

For investors prioritizing present income durability, Healthpeak has the stronger case. Pfizer is the more event-driven choice because dividend safety increasingly depends on product launches, clinical results and management's ability to rebuild cash flow after the COVID decline.